Report Overview

The US CAR T-Cell Therapy market is estimated to grow at a CAGR xx% from the market size xx million in 2019 to xx million in 2028

The US dominated the market globally in 2019 and is likely to continue to command during the assessment period. The growth in this region can be attributed to the increasing cases of cancer. According to the data published by the American Cancer Society, about 1,688,780 new cases were registered in 2017 in the US. Furthermore, in the US, there were an estimated 1,762,450 new cancer cases diagnosed and 606,880 deaths due to cancer in 2019. These factors drive the growth of this market



Market Drivers

The prevalence of cancers is increasing the demand for effective treatment. According to the National Cancer Institute, approximately 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Excessive smoking and consumption of alcohol and tobacco are factors increasing the prevalence of cancer

Major CAR T-Cell Therapy Market by Disease Indication

The major disease includes Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma and Others.